SG&A expenses were $9.7 million for the current quarter, which is an increase of $6.4 million when compared to the same period last year. This was driven by an increase of $3 million in compensation expenses as a result of increased headcount, a $1.2 million increase in marketing and advertising expenses, primarily related to the commercialization of Barostim in the U.S., a $600,000 increase in non-cash stock-based compensation expense, a $700,000 increase related to D&O insurance costs incurred as a result of becoming a public company, and a $500,000 increase in travel expenses.

Feb 15, 2022 / CFO / receipt, needs a key / Jared Washine, CFO | earnings call 2022-02-15 | transcript dc82e849-a1cf-4408-80a2-23f1a3a9a73b | chars 7307-7893 | segment 7